Molecular Targets of Cannabidiol in Neurological Disorders.

Authors: Clementino Ibeas Bih, Tong Chen, Alistair V. W. Nunn, Michaël Bazelot, et al
Neurotherapeutics, October 2015

Cannabis has a long history of anecdotal medicinal use and limited licensed medicinal use. Until recently, alleged clinical effects from anecdotal reports and the use of licensed cannabinoid medicines are most likely mediated by tetrahydrocannabinol by virtue of: 1) this canna…

Cannabinoids for the Treatment of Movement Disorders.

Authors: Briony Catlow, Juan Sanchez-Ramos
Current Treatment Options in Neurology, September 2015

Use of cannabinoids as medications has a long history. Unfortunately, the prohibition of cannabis and its classification in 1970 as a schedule 1 drug has been a major obstacle in studying these agents in a systematic, controlled manner. The number of class 1 studies (randomize…

Turning Over a New Leaf: Cannabinoid and Endocannabinoid Modulation of Immune Function.

Authors: Guy A. Cabral, Thomas J. Rogers, Aron H. Lichtman
Journal of Neuroimmune Pharmacology, June 2015

Cannabis is a complex substance that harbors terpenoid-like compounds referred to as phytocannabinoids. The major psychoactive phytocannabinoid found in cannabis ∆(9)-tetrahydrocannabinol (THC) produces the majority of its pharmacological effects through two cannabinoid recep…

Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders.

Authors: Barbara S. Koppel, John C.M. Brust, Terry Fife, Jeff Bronstein, Sarah Youssof, et al
Neurology, 29 April 2014

OBJECTIVE: To determine the efficacy of medical marijuana in several neurologic conditions. METHODS: We performed a systematic review of medical marijuana (1948-November 2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We gra…

A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain.

Authors: Barth Wilsey, Thomas Marcotte, Alexander Tsodikov, Jeanna Millman, Heather Bentley, et al
The Journal of Pain, June 2008

The Food and Drug Administration (FDA), Substance Abuse and Mental Health Services Administration (SAMHSA), and the National Institute for Drug Abuse (NIDA) report that no sound scientific studies support the medicinal use of cannabis. Despite this lack of scientific validatio…

Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine.

Authors: Ethan B. Russo, Geoffrey W. Guy, Philip J. Robson
Chemistry & Biodiversity, August 2007

Cannabis sativa L. has been utilized for treatment of pain and sleep disorders since ancient times. This review examines modern studies on effects of Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on sleep. It goes on to report new information on the effects on sleep…

Pain measurements and side effect profile of the novel cannabinoid ajulemic acid.

Authors: Kahlid Salim, Udo Schneider, Sumner Burstein, Ludwig Hoy, Matthias Karst
Neuropharmacology, June 2005

Preclinical findings on ajulemic acid (AJA) showed analgesic and anti-allodynic effects without psychoactive properties making it an appealing substance for the treatment of pain. A recently published randomized double-blind crossover clinical trial described the pain-reducing…